Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes

Zeidan, Amer M.; Joshi, Nikita; Kale, Hrishikesh; Wang, Wei-Jhih; Corman, Shelby; Salimi, Tehseen; Epstein, Robert S.

doi:10.1016/j.clml.2022.04.016

Cited by 3 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, older patients are often frail and have many comorbidities that make it difficult to continue the treatment. In fact, almost one-third of high-risk MDS patients treated with HMAs discontinue treatment before four cycles, and nearly half of these patients discontinue after only one cycle [ 5 ]. Older age and poor performance status are also reported to be predictors of HMA discontinuation [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

“…In fact, almost one-third of high-risk MDS patients treated with HMAs discontinue treatment before four cycles, and nearly half of these patients discontinue after only one cycle [ 5 ]. Older age and poor performance status are also reported to be predictors of HMA discontinuation [ 5 ]. Continued administration of AZA for MDS requires early identification of the patient group most likely to experience serious adverse events that would cause discontinuation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine

Takada,

Nakamura,

Kaneda

et al. 2024

Hematology Reports

View full text Add to dashboard Cite

Background: Azacitidine (AZA) is the standard treatment for patients with high-risk myelodysplastic syndromes (MDS). The impact of skeletal muscle depletion (SMD), which is associated with outcomes of hematological malignancies, on the clinical course of MDS patients treated with AZA was investigated. Methods: This retrospective, observational study included 50 MDS patients treated with AZA. Muscle mass was evaluated using the skeletal muscle index (SMI), which is the area of muscle mass at the third lumbar vertebra on CT images divided by the square of the height. Results: Of the enrolled patients, 39 were males, and their median age was 69.5 years. Twenty-seven (20 male and 7 female) patients showed SMD. The median survival was 13.4 months in the SMD group and 15.2 months in the non-SMD group, with no significant difference and no significant association between the response rate or severe non-hematological toxicities and the presence of SMD. By contrast, grade 3–4 anemia and thrombocytopenia were significantly more frequent in the SMD group than in the non-SMD group. SMD was associated with severe anemia and thrombocytopenia in MDS patients treated with AZA. Conclusion: Reduced skeletal muscle mass may predict severe hematological toxicity in MDS patients treated with AZA.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine

Takada,

Nakamura,

Kaneda

et al. 2024

Hematology Reports

View full text Add to dashboard Cite

show abstract

“… 14 , 15 In retrospective claims analyses conducted in the United States between 2010 and 2020, it was reported that 44%–65% of patients with HR-MDS did not receive IV/SC HMA therapy. 14 – 17 Furthermore, among patients who received IV/SC HMAs, 44% were non-persistent with therapy, discontinuing before four cycles of therapy or having a gap of 90 days or more between consecutive HMA cycles. 14 , 16 , 17 …”

Section: Introductionmentioning

confidence: 99%

“… 14 – 17 Furthermore, among patients who received IV/SC HMAs, 44% were non-persistent with therapy, discontinuing before four cycles of therapy or having a gap of 90 days or more between consecutive HMA cycles. 14 , 16 , 17 …”

Section: Introductionmentioning

confidence: 99%

“… 14 HMA underuse is also associated with a burden on healthcare resource utilization (HCRU), with higher total per-patient-per-month healthcare costs reported among patients who were non-persistent with HMAs compared with those who were persistent ($18,039 versus $13,893). 16 – 18 Previous studies on patients’ experiences with IV/SC HMA therapy have highlighted the treatment burden associated with parenteral HMA administration. 19 , 20 In a prior survey conducted in the United States, patients reported pain and anxiety before and during IV/SC HMA therapy, interference with daily activities, and logistical challenges related to IV/SC administration of HMAs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms

Zeidan,

Perepezko,

Salimi

et al. 2024

Therapeutic Advances in Hematology

Self Cite

View full text Add to dashboard Cite

Background: Hypomethylating agents (HMAs) are guideline-recommended treatment for higher-risk myelodysplastic syndromes/neoplasms (MDS). However, a prior survey of patients with MDS reported challenges with intravenous (IV) and subcutaneous (SC) HMA therapies, including pain related to treatment administration and interference with daily activities; most patients also indicated a preference to switch to an oral therapy if one were available. Objectives: This study evaluated the perspectives of US patients with MDS receiving oral decitabine/cedazuridine (DEC-C), an alternative to IV/SC HMAs. Methods: An online survey was conducted among adult patients with MDS in the United States (10 November 2022 to 5 December 2022) who had filled a prescription for oral DEC-C between 2021 and 2022. Results: A total of 150 patients completed the survey; 61% were aged ⩾60 years and 63% were male. Of these, 123 (82%) were still receiving oral DEC-C, and 27 (18%) had stopped oral DEC-C treatment. Half (50%) of patients had received oral DEC-C for ⩾6 months. The majority reported that treatment was convenient (83%) and that they were satisfied with treatment (86%). Most patients also reported very little/no interference with regular daily activities (82%), social activities (78%), and productivity (78%). When queried about negative impacts on quality of life (QOL), treatment side effects were the most commonly reported (30% of respondents). Among patients who had previously received IV/SC HMAs ( n = 91), most agreed that oral DEC-C interfered less with daily life (91%) and had experienced improvement in QOL (85%) compared with previous treatment; 91% reported that oral DEC-C reduced the number of times they needed to travel to a healthcare facility. Conclusion: Survey results suggest very little/no impact on regular daily activities and improved QOL with oral DEC-C relative to IV/SC HMAs, highlighting the potential for oral DEC-C to reduce the treatment burden associated with parenteral HMA therapy.

show abstract

Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices

Egloff,

Cao,

Lachs

et al. 2023

Leukemia & Lymphoma

View full text Add to dashboard Cite

Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes

Cited by 3 publications

References 28 publications

Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine

Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine

Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms

Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices

Contact Info

Product

Resources

About